tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Halozyme sees FY24 revenue $620M-$630M, consensus $614.12M

Sees FY24 APEI Net income available to common stockholders $8M-$14M; Adjusted EBITDA $60M-$70M, up 1%-17% from FY23; Capital Expenditure $17M-$20M, up 22%-44% from FY23.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1